TokenPost·
Revelation Biosciences Posts $5.92 GAAP Loss Per Share in Q3 2026
Cash and cash equivalents were $9.1 million on Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025.
More news
- TokenPostWestern Forest Products Narrows Q3 Loss to C$5.2 Million as Revenue Rises
- TokenPostPremium Brands Posts C$2.4B in Q3 Continuing-Operations Revenue
- TokenPostLB Pharmaceuticals Posts $1.79 Loss Per Share in Third Quarter
- TokenPostCZ Urges iPhone Users to Update iOS as DarkSword Puts Data at Risk
- TokenPostSimon Property Group Raises 2026 FFO Guidance to $13.30-$13.40
- TokenPostHyperliquid Strategies Unit Applies for U.S. Futures Broker Registration